Biotech firm Zymeworks' Q2 revenue jumps to $48.7 mln

Reuters
08/08
Biotech firm Zymeworks' <a href="https://laohu8.com/S/QTWO">Q2</a> revenue jumps to $48.7 mln

Overview

  • Zymeworks Q2 2025 revenue rises to $48.7 mln, driven by milestone payments

  • Net income for Q2 2025 reaches $2.3 mln, reversing last year's loss

  • FDA clears IND for ZW251, first-in-human studies planned for 2025

Outlook

  • Company expects cash resources to fund operations into 2H-2027

Result Drivers

  • MILESTONE PAYMENTS - $20 mln milestone from BeOne for zanidatamab approval in China and $7.5 mln from BMS commercial license option

  • PARTNERSHIP REVENUE - Revenue driven by strategic partnerships and collaborations, including Jazz and J&J

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q2 Net Income

$2.32 mln

Q2 Income From Operations

-$674,000

Q2 Operating Expenses

$49.40 mln

Q2 Pretax Profit

$2.13 mln

Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for Zymeworks Inc is $19.50, about 36.4% above its August 6 closing price of $12.41

Press Release: ID:nGNXtVNdB

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10